MNG523
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.555
- ALLOGRAFT_REJECTION+0.522
- INTERFERON_GAMMA_RESPONSE+0.498
- IL6_JAK_STAT3_SIGNALING+0.441
- INTERFERON_ALPHA_RESPONSE+0.426
- INFLAMMATORY_RESPONSE+0.413
- ANGIOGENESIS+0.366
- COMPLEMENT+0.351
- MYOGENESIS+0.319
- WNT_BETA_CATENIN_SIGNALING+0.313
Top 10 suppressed
- MYC_TARGETS_V2-0.296
- OXIDATIVE_PHOSPHORYLATION-0.282
- CHOLESTEROL_HOMEOSTASIS-0.258
- ESTROGEN_RESPONSE_EARLY-0.223
- SPERMATOGENESIS-0.183
- BILE_ACID_METABOLISM-0.173
- MYC_TARGETS_V1-0.162
- MTORC1_SIGNALING-0.121
- ESTROGEN_RESPONSE_LATE-0.092
- HEME_METABOLISM-0.069
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.873 |
| 2 | MDT-AP-0390 | Med | Medulloblastoma | 0.871 |
| 3 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.868 |
| 4 | BSR_10_0229_A4_S93 | — | D | 0.856 |
| 5 | TCGA-OR-A5J8-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.855 |
| 6 | c55bb20b-c929-42e2-be7f-8b1da7bee953 | — | — | 0.853 |
| 7 | SAMN03290911 | — | — | 0.853 |
| 8 | R187 | — | — | 0.852 |
| 9 | TCGA-MP-A4TI-01A-21R-A24X-07 | — | cohortA1 | 0.852 |
| 10 | TCGA-CV-7090-01A-11R-2016-07 | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.555 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.522 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.498 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.441 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.426 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.413 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.366 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.351 | Inavolisib | — uncovered |
| MYOGENESIS | 0.319 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.313 | Inavolisib | — uncovered |
| COAGULATION | 0.294 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.259 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.242 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.212 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.207 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.165 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.163 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.162 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.158 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.155 | Inavolisib | — uncovered |